

# DoD/FDA Shelf Life Extension Program (SLEP)

Defense Medical Standization Board (DMSB Joint Readiness Clinical Advisory Board (JRCA)



## DMSB/JRCAB History and

Mission

- Began in 1945 as the Army-Navy Specification Cataloging Committee
- In 1984 became the Defense Medical Standardization Board (DMSB)
- 1986 DMSB tasked as Quad Service interface to the FDA for the DoD/FDA SLEP
- In 1998 name provisionally changed to Joint Readiness Clinical Advisory Board (JRCAB)
- In 2002, FDA allowed the National Strategic Pharmaceutical Stockpile (NSPS) to be added to the DoD/FDA SLEP under the JRCAB interface to the FDA
- 2003- updating and moving the automation for DoD/FDA SLEP to an Oracle/Web system

#### MISSION

- Maintain the DoD/FDA Shelf Life Extension Program
- Provide standardized clinical patient treatment protocols for patient conditions (PCs)
- Standardized medical materiel/resources for delivery of healthcare in deployable medical systems (DEPMEDS) and in the Military Health Services System

**UNCLASSIFIED** 



- All Pharmaceutics are controlled by the FDA
- New products (including new manufacturers or change in packaging/manufacturing) are given a maximum of a 2 year Shelf Life
- The DoD/FDA SLEP is limited to:

Army Air Force DSCP (does not currently Navy Marines participate)
Strategic National Stockpile (SNS)

NO other Federal or Civilian agency may legally use the program



- Substantial investments in replacement costs for war reserve potency dated medical material
  - Replacement cost in 1986 \$2.5 million subject of GAO Audit
- July 1985 AF/SG office and FDA met
  - Established pilot project for concept testing
  - FDA established test protocols for 56 listed items
  - O Samples of 56 items were sent to the FDA



- ➤ January 1986 interagency agreement was signed forming the program
- DMSB tasked as Quad-Service focal point
- ➤ In FY 1991 FDA increased dedicated program resources (facilities & personnel) due to expansion of new and retest projects



MSB/JRCAB serves a Liaison between ervices /SNS & FD/

Services submit Samples for testing

FDA tests
Military/contingency
significant
medications



ost Avoidance to DoD Of \$2.3M for \$600K of testing in FY03 FDA grants extension or denies extension of shelf-life, by Lot and NSN





- Current testing focuses on military significant items
  - Drugs that are manufactured specifically for military use e.g. auto-injectors, CANA, atropine, 2-Pam chloride....
  - Drugs that are purchased in very large quantities for specific contingency needs - e.g. Ciprofloxacin
  - Items that can not be return **Returns Programs**
- Other drug products are co case-by-case



- **▶**Test selection criteria:
  - Item cannot be a biological
  - FDA must have a test protocol for the item
  - Manufacturer's data for the item does not indicate previous instability
  - Cost beneficial for testing
  - O Materiel must be stored under the manufacturer's recommended temperature
- ► FDA requests samples, various storage locations and lots, through DMSB/JRCAB to the Service field agency




- Field activities send samples to the FDA
- ➤ Products are tested and results are reported to the DMSB/JRCAB
- DMSB/JRCAB updates SLEP database, computes financial benefit and cost, orders labels (Dec 04) and distributes the information to the appropriate Service field agency
- >Tested products are re-tested annually





#### FDA Testing

- ➤ Test protocols from manufacturer's original product test data
- Accelerated testing (stress testing)
  - Designed to increase rate of chemical or physical degradation using exaggerated storage conditions
- Potency of stressed samples compared to standard for each item
  - Results in estimated extendible life of the product





- FDA testing time-frame
  - ➤ 8 months from the time the DMSB/JRCAB presents a project candidate list until project's extension information received by DMSB/JRCAB
- ► FDA testing is comprehensive and scientifically sound
  - Date extensions are conservative estimates of useful life of the product as substantiated by stress testing
- FDA grants extensions for all DoD facilities having the tested material stored under same conditions
  - Material specified by manufacturer, expiration date, lot number and storage condition



What materiel may be extended?

- Original Packaging or repacked by an approved FDA procedure.
- Must be stored at correct environmental standards IAW manufacturers literature.
- May not have been issued to an individual
- ➤ No leakage or failure of packaging, to include particles in solution, bulging or damage to packaging so product identification is missing or hard to read.



Average cost avoidance ratio is \$71.00 for each dollar spent on testing in FY 03.

Sample of cost for testing a lot is:

Atropine Injectors \$1850.00


Ciprofloxacin \$1800.00

0 2-Pam chloride \$1000.00

O CANA \$2500.00



#### **Total Inventory Values By Service**




■ FY02 **■** FY03

Inventory Value




#### **Retum on Investment**






#### **Cost Avoidance**





#### **Cost of Testing**



UNCLASSIFIED

SLEP currently operates in a clientserver environment. Operators access the application, both the GUI and the database management system thru their desktop. The SLEP program is hosted in Microsoft Access 2000. A subcomponent of the SLEP system is hosted in Cold Fusion on the JRCAB current Web site. This component provides limited query capability. Only the POC from 3 of the 4 Services have access to the System. The Project Manager and Service POC mustassified

Changes in the DoD/FDA SLEP Progra



The DMSB/JRCAB is currently moving to a DoD-approved/compliant enterprise level (Oracle), data base management system (DBMS). The GUI portion is migrating to a Web-based environment. This supports widened accessibility to the operators. The operators will now include all activities who have medical materiel on hand, that is in the **DoD/FDA SLEP Program** 



- ► Moving the MMQC function from USAMMA to DMSB/JRCAB
- Change in the automation system for medical cataloging



#### **▶**New Innovations :

- New Customers to the Program, the SNS, Post Office and possibly the VA.
- Addition of new products to program thought the SNS and New Military Unique items (i.e RSDL, QuickClot, HemoCon Bandage ...)
- Addition of contract support
- O Increase interface with other DoD and DoD SLEP systems, e.g. JMAR, DoD SLEP ...



## FDA Re-labeling Requirements

Food and Drug Administration Relabeling Mandate of 2002 is being modified. Waiting for final decision from the FDA.







#### **POCs:**

(301) 619-4074

(301) 619-4126

